These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 21393385

  • 1. The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.
    Ezzoukhry Z, Louandre C, François C, Saidak Z, Godin C, Mazière JC, Galmiche A.
    Mol Pharmacol; 2011 Jun; 79(6):997-1004. PubMed ID: 21393385
    [Abstract] [Full Text] [Related]

  • 2. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N.
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [Abstract] [Full Text] [Related]

  • 3. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
    Karlberg M, Ekoff M, Huang DC, Mustonen P, Harvima IT, Nilsson G.
    J Immunol; 2010 Aug 15; 185(4):2555-62. PubMed ID: 20639495
    [Abstract] [Full Text] [Related]

  • 4. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
    Kuroda J, Kimura S, Strasser A, Andreeff M, O'Reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Tabe Y, Taniwaki M, Maekawa T.
    Cell Death Differ; 2007 Sep 15; 14(9):1667-77. PubMed ID: 17510658
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
    Lee SJ, Park HJ, Kim YH, Kim BY, Jin HS, Kim HJ, Han JH, Yim H, Jeong SY.
    Int J Mol Med; 2012 Aug 15; 30(2):443-50. PubMed ID: 22664653
    [Abstract] [Full Text] [Related]

  • 6. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.
    Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, Lust JA, Greipp PR, Kumar S.
    Leukemia; 2007 Jul 15; 21(7):1549-60. PubMed ID: 17460700
    [Abstract] [Full Text] [Related]

  • 7. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.
    Clin Cancer Res; 2007 Dec 01; 13(23):7191-8. PubMed ID: 18056200
    [Abstract] [Full Text] [Related]

  • 8. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
    Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, Huang DC, Weninger W, Haass NK, Allen JD.
    Clin Cancer Res; 2012 Feb 01; 18(3):783-95. PubMed ID: 22173547
    [Abstract] [Full Text] [Related]

  • 9. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
    Kohl TM, Hellinger C, Ahmed F, Buske C, Hiddemann W, Bohlander SK, Spiekermann K.
    Leukemia; 2007 Aug 01; 21(8):1763-72. PubMed ID: 17554384
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP.
    J Natl Cancer Inst; 2008 Apr 16; 100(8):580-95. PubMed ID: 18398104
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
    Lieber J, Kirchner B, Eicher C, Warmann SW, Seitz G, Fuchs J, Armeanu-Ebinger S.
    Pediatr Blood Cancer; 2010 Dec 01; 55(6):1089-95. PubMed ID: 20680965
    [Abstract] [Full Text] [Related]

  • 12. BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma.
    Galmiche A, Ezzoukhry Z, François C, Louandre C, Sabbagh C, Nguyen-Khac E, Descamps V, Trouillet N, Godin C, Regimbeau JM, Joly JP, Barbare JC, Duverlie G, Mazière JC, Chatelain D.
    Mol Cancer Res; 2010 Aug 01; 8(8):1116-25. PubMed ID: 20647330
    [Abstract] [Full Text] [Related]

  • 13. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
    Séveno C, Loussouarn D, Bréchet S, Campone M, Juin P, Barillé-Nion S.
    Breast Cancer Res; 2012 Jun 15; 14(3):R96. PubMed ID: 22703841
    [Abstract] [Full Text] [Related]

  • 14. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
    Russo M, Spagnuolo C, Volpe S, Tedesco I, Bilotto S, Russo GL.
    Biochem Pharmacol; 2013 Apr 01; 85(7):927-36. PubMed ID: 23353698
    [Abstract] [Full Text] [Related]

  • 15. Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells.
    Aranovich A, Liu Q, Collins T, Geng F, Dixit S, Leber B, Andrews DW.
    Mol Cell; 2012 Mar 30; 45(6):754-63. PubMed ID: 22464442
    [Abstract] [Full Text] [Related]

  • 16. Targeting multiple arms of the apoptotic regulatory machinery.
    Dai Y, Grant S.
    Cancer Res; 2007 Apr 01; 67(7):2908-11. PubMed ID: 17409392
    [Abstract] [Full Text] [Related]

  • 17. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
    High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB.
    Mol Pharmacol; 2010 Mar 01; 77(3):483-94. PubMed ID: 20038611
    [Abstract] [Full Text] [Related]

  • 18. The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells.
    Allaman-Pillet N, Oberson A, Munier F, Schorderet DF.
    Ophthalmic Genet; 2013 Mar 01; 34(1-2):1-13. PubMed ID: 21955141
    [Abstract] [Full Text] [Related]

  • 19. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, Fesik SW, Shen Y.
    Oncogene; 2007 Jun 07; 26(27):3972-9. PubMed ID: 17173063
    [Abstract] [Full Text] [Related]

  • 20. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
    Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, Herold-Mende C, Roth W.
    Oncogene; 2008 Nov 06; 27(52):6646-56. PubMed ID: 18663354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.